Beta Bionics has developed the iLet Bionic Pancreas, an advanced insulin delivery system designed to simplify diabetes management. This innovative device utilizes data from continuous glucose monitors (CGMs) such as the Dexcom G7 and the FreeStyle Libre 3 Plus sensor to autonomously determine and administer insulin doses. By learning the user's insulin needs, the iLet eliminates the necessity for manual carb counting and insulin dose calculations, thereby reducing the cognitive burden often associated with diabetes management. The latest iteration, the Color iLet, features a vibrant display that enhances user interaction by providing clear glucose readings, meal notifications, and audible alerts.

In addition to its core functionality, Beta Bionics emphasizes community support through the Bionic Circle, allowing users to connect with friends and family for shared experiences and encouragement. The company is committed to continuous improvement and user feedback, as evidenced by their recent updates and partnerships aimed at enhancing the iLet's capabilities. With a focus on making diabetes management more intuitive and less intrusive, Beta Bionics aims to empower individuals living with diabetes to lead more fulfilling lives.

United States

Beta Bionics is a commercial stage medical technology company engaged in the design, development, and commercialization of innovative solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWDs) by utilizing advanced adaptive algorithms to simplify and improve the treatment of their disease. The iLet Bionic Pancreas is the first FDA-cleared autonomous insulin delivery device in the market and offers the potential to substantially improve overall outcomes across broad populations of PWDs. To learn more, visit www.betabionics.com.

For safety information, visit: www.betabionics.com/safety. 

Beta Bionics

Company Details